Jiangxi Synergy Pharmaceutical Co Ltd (300636) - Net Assets
Based on the latest financial reports, Jiangxi Synergy Pharmaceutical Co Ltd (300636) has net assets worth CN¥2.38 Billion CNY (≈ $348.86 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.31 Billion ≈ $484.59 Million USD) and total liabilities (CN¥927.61 Million ≈ $135.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Jiangxi Synergy Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.38 Billion |
| % of Total Assets | 71.99% |
| Annual Growth Rate | 35.52% |
| 5-Year Change | 166.32% |
| 10-Year Change | 676.36% |
| Growth Volatility | 37.84 |
Jiangxi Synergy Pharmaceutical Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Jiangxi Synergy Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Jiangxi Synergy Pharmaceutical Co Ltd (300636) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Jiangxi Synergy Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual net assets of Jiangxi Synergy Pharmaceutical Co Ltd from 2012 to 2025. For live valuation and market cap data, see Jiangxi Synergy Pharmaceutical Co Ltd (300636) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.37 Billion ≈ $346.11 Million |
+2.45% |
| 2024-12-31 | CN¥2.31 Billion ≈ $337.84 Million |
+3.70% |
| 2023-12-31 | CN¥2.23 Billion ≈ $325.80 Million |
+68.71% |
| 2022-12-31 | CN¥1.32 Billion ≈ $193.11 Million |
+48.59% |
| 2021-12-31 | CN¥888.11 Million ≈ $129.96 Million |
+8.77% |
| 2020-12-31 | CN¥816.50 Million ≈ $119.48 Million |
+15.60% |
| 2019-12-31 | CN¥706.31 Million ≈ $103.36 Million |
+7.32% |
| 2018-12-31 | CN¥658.16 Million ≈ $96.31 Million |
+3.31% |
| 2017-12-31 | CN¥637.10 Million ≈ $93.23 Million |
+109.12% |
| 2016-12-31 | CN¥304.66 Million ≈ $44.58 Million |
+23.51% |
| 2015-12-31 | CN¥246.66 Million ≈ $36.09 Million |
+108.99% |
| 2014-12-31 | CN¥118.02 Million ≈ $17.27 Million |
+49.75% |
| 2013-12-31 | CN¥78.82 Million ≈ $11.53 Million |
+73.19% |
| 2012-12-31 | CN¥45.51 Million ≈ $6.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangxi Synergy Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2190.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥624.45 Million | 26.40% |
| Other Components | CN¥1.74 Billion | 73.60% |
| Total Equity | CN¥2.37 Billion | 100.00% |
Jiangxi Synergy Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangxi Synergy Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Greene County Bancorp Inc
NASDAQ:GCBC
|
$406.26 Million |
|
Doright Co.Ltd.
SHE:300950
|
$406.27 Million |
|
Suzhou Kelida Bldg &
SHG:603828
|
$406.39 Million |
|
Beijing Fjr Optoelectronic Technology Co Ltd
SHG:688272
|
$406.48 Million |
|
First Bank
NASDAQ:FRBA
|
$406.04 Million |
|
Shenzhen Prolto Supply Chain Management Co Ltd
SHE:002769
|
$405.89 Million |
|
Palm Landscape Architecture Co Ltd
SHE:002431
|
$405.87 Million |
|
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
|
$405.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangxi Synergy Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,308,747,885 to 2,365,234,648, a change of 56,486,763 (2.4%).
- Net income of 73,091,433 contributed positively to equity growth.
- Dividend payments of 28,778,547 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥73.09 Million | +3.09% |
| Dividends Paid | CN¥28.78 Million | -1.22% |
| Other Changes | CN¥12.17 Million | +0.51% |
| Total Change | CN¥- | 2.45% |
Book Value vs Market Value Analysis
This analysis compares Jiangxi Synergy Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.25x to 1.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.31 | CN¥6.61 | x |
| 2013-12-31 | CN¥0.54 | CN¥6.61 | x |
| 2014-12-31 | CN¥0.61 | CN¥6.61 | x |
| 2015-12-31 | CN¥1.12 | CN¥6.61 | x |
| 2016-12-31 | CN¥1.32 | CN¥6.61 | x |
| 2017-12-31 | CN¥2.19 | CN¥6.61 | x |
| 2018-12-31 | CN¥2.11 | CN¥6.61 | x |
| 2019-12-31 | CN¥2.27 | CN¥6.61 | x |
| 2020-12-31 | CN¥2.64 | CN¥6.61 | x |
| 2021-12-31 | CN¥2.63 | CN¥6.61 | x |
| 2022-12-31 | CN¥3.81 | CN¥6.61 | x |
| 2023-12-31 | CN¥5.85 | CN¥6.61 | x |
| 2024-12-31 | CN¥5.50 | CN¥6.61 | x |
| 2025-12-31 | CN¥5.63 | CN¥6.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangxi Synergy Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.82%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.40x
- Recent ROE (3.09%) is below the historical average (12.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 17.64% | 7.67% | 0.55x | 4.15x | CN¥3.48 Million |
| 2013 | 21.42% | 11.93% | 0.60x | 2.99x | CN¥9.00 Million |
| 2014 | 33.22% | 18.44% | 0.83x | 2.18x | CN¥27.41 Million |
| 2015 | 25.49% | 22.88% | 0.79x | 1.41x | CN¥38.21 Million |
| 2016 | 19.04% | 23.19% | 0.60x | 1.38x | CN¥27.53 Million |
| 2017 | 10.27% | 22.06% | 0.41x | 1.13x | CN¥1.75 Million |
| 2018 | 3.73% | 9.18% | 0.33x | 1.22x | CN¥-41.29 Million |
| 2019 | 6.84% | 11.70% | 0.41x | 1.44x | CN¥-22.32 Million |
| 2020 | 8.58% | 16.09% | 0.30x | 1.80x | CN¥-11.60 Million |
| 2021 | 9.13% | 13.70% | 0.31x | 2.15x | CN¥-7.69 Million |
| 2022 | 7.63% | 13.98% | 0.32x | 1.71x | CN¥-31.30 Million |
| 2023 | 4.76% | 14.68% | 0.22x | 1.45x | CN¥-116.66 Million |
| 2024 | 4.62% | 14.04% | 0.23x | 1.44x | CN¥-124.29 Million |
| 2025 | 3.09% | 8.82% | 0.25x | 1.40x | CN¥-163.43 Million |
Industry Comparison
This section compares Jiangxi Synergy Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,819,786,107
- Average return on equity (ROE) among peers: 5.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangxi Synergy Pharmaceutical Co Ltd (300636) | CN¥2.38 Billion | 17.64% | 0.39x | $406.20 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $5.88 Billion | 7.12% | 1.83x | $612.18 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $536.15 Million | 4.62% | 0.32x | $371.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.52 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $13.64 Billion | 12.57% | 0.51x | $2.56 Billion |
| Wedge Industrial Co Ltd (000534) | $549.14 Million | 1.31% | 0.01x | $2.22 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $12.90 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $734.70 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $271.26 Million | 1.07% | 1.01x | $324.84 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.60 Billion | -10.44% | 3.72x | $929.28 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $9.75 Billion | 6.63% | 0.12x | $3.13 Billion |
About Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd. engages in research and development, production, and sales of chemical raw materials and pharmaceutical intermediates in China and internationally. The company offers nervous system drugs, digestive system medications, antipyretic analgesics and non-steroidal anti-inflammatory analgesics, antihypertensive drugs, anticoagulants, hypoglycemic drugs, antidepr… Read more